Brought to you by 
Roche gets rights to SmithKline's Kytril
18 Jun 2014
Executive Summary
Upon final completion of its merger with Glaxo Wellcome, SmithKline Beecham will sell its anti-emitic drug Kytril (granisetron hydrochloride), indicated for chemotherapy, radiotherapy, and postoperative nausea and vomiting, to Roche for $1.23bn in cash.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche gets rights to SmithKline's Kytril
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice